Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Estimated FDA User Fee Review Goals For Pending NDAs/BLAs

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary


You may also be interested in...

Year-End Submission Rate Stabilizes In 2005 As NDA Approvals Drop

The slow-down in year-end FDA submissions in recent years appears to have stabilized in 2005, with 16 filings in December – up slightly from 13 in December 2004.

Symlin Dose Titration Mitigates Hypoglycemia, Nausea, Amylin Says

Amylin’s recent Symlin NDA amendment shows that a dose titration regimen reduces the risks of nausea and hypoglycemia in type 1 and 2 diabetes patients, the firm reported June 15.

Zavesca User Fee Goal In August; EU Review Raises Neurotoxicity Concerns

European review documents for Oxford GlycoSciences/Actelion’s Gaucher disease treatment Zavesca raise two concerns that are likely issues in FDA’s review: comparative efficacy to enzyme replacement therapy and neurological adverse events.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts